News | October 25, 2025
Syngene International expands capabilities with new bioconjugation suite in Bengaluru
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
Kushwaha previously served as Chief Digital & Information Officer at Jubilant Ingrevia Limited
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
This year, 40 women students are participating, selected through a rigorous process evaluating academic merit, research interest, and socio-economic background
The inspection concluded successfully, with the facility found to be in compliance with the required regulations
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
He has global experience in strategic and operational leadership levels with an extensive track record of leadership and success in building companies, businesses, teams, and brands for over 30 years
The new site will increase Syngene's total single-use bioreactor capacity to 50,000L
Overall investment in the US facility is estimated around US$50 million
Subscribe To Our Newsletter & Stay Updated
